Evidence map›Paper›PMID 40890856›Full record

ArticleDiagnostic pathology2025

Prognostic impact of RPL15 overexpression in intrahepatic cholangiocarcinoma: a marker of aggressive tumor behavior.

Wen-Ching Wang, Chien-Jui Huang, Han-Ping Hsu, Yu-Hsuan Kuo, Khaa Hoo Ong, Ding-Ping Sun, Yu-Feng Tian, Chia-Ling Chou, Ti-Chun Chan, Chung-Hsi Hsing and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wen-Ching Wang *Division of Gastroenterology & General Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
Chien-Jui Huang *Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Han-Ping Hsu *Section of Plastic Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
Yu-Hsuan KuoDivision of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.
Khaa Hoo OngDivision of Gastroenterology & General Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
Ding-Ping SunDivision of Gastroenterology & General Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
Yu-Feng TianDivision of Gastroenterology & General Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
Chia-Ling ChouDivision of Gastroenterology & General Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
Ti-Chun ChanDepartment of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
Chung-Hsi HsingDepartment of Anesthesiology, Chi Mei Medical Center, Tainan, Taiwan.
Wan-Shan LiInstitute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan.
Hong-Lin HeDepartment of Pathology, E-DA Cancer Hospital, I-Shou University, Kaohsiung, Taiwan. baltic1023@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOverexpression of ribosomal proteins has been found in several cancer types and has an important role in cell proliferation and tumorigenesis. Analysis of the expression profiles of cholangiocarcinoma revealed that ribosomal protein L15 (RPL15) was significantly upregulated in cancer tissues compared to surrounding liver and biliary tissues. Thus, we tried to investigate the role of RPL15 in intrahepatic cholangiocarcinoma.

methodsThe expression of RPL15 in intrahepatic cholangiocarcinoma was assessed using immunohistochemistry. The relationships between RPL15 expression levels and clinicopathological parameters were analyzed, along with investigating its prognostic significance in overall survival (OS), disease-specific survival (DSS), local recurrence-free survival (LRFS) and metastasis-free survival (MeFS).

resultsIn the cohort comprising 182 patients with intrahepatic cholangiocarcinoma, high expression of RPL15 was significantly associated with advanced tumor (pT) stage (P = 0.005) and high histological grade (P = 0.018). In univariate analyses, overexpression of RPL15 predicted worse DSS (P = 0.0001), LRFS (P < 0.0001) and MeFS (P < 0.0001), but not OS (P = 0.3960). Multivariate analyses revealed that RPL15 overexpression independently predicted worse DSS (P = 0.039), LRFS (P < 0.001) and MeFS (P < 0.001).

conclusionsOverexpression of RPL15 was identified as an adverse prognostic factor predicting worse outcomes in intrahepatic cholangiocarcinoma. RPL15 could serve as a potential therapeutic target to aid in developing new treatment strategies.

Indexed as

Bile Duct NeoplasmsBiomarkers, TumorCholangiocarcinomaRibosomal ProteinsAdultAgedDisease-Free SurvivalFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedPrognosisUp-RegulationBiomarkers, TumorRibosomal ProteinsCholangiocarcinomaExpression profilePrognostic factorRibosomal protein L15RPL15

Identifiers

PMID40890856
PMCPMC12400670

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.